Medicare Advantage Population in the United States: Outcomes of Patients with Asthma Treated with ICS/LABA Before and After Initiation with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI).
Saved in:
| Title: | Medicare Advantage Population in the United States: Outcomes of Patients with Asthma Treated with ICS/LABA Before and After Initiation with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI). |
|---|---|
| Authors: | Baptist AP; Division of Allergy and Clinical Immunology, Henry Ford Health and MI State University Health Sciences, One Ford Place, 3A32, Detroit, MI, 48202, USA. abaptis1@hfhs.org., Germain G; Group d'Analyse, Ltée, Montreal, QC, Canada., Klimek J; Analysis Group, Inc, Boston, MA, USA., Laliberté F; Group d'Analyse, Ltée, Montreal, QC, Canada., Schell RC; Analysis Group, Inc, Menlo Park, CA, USA., Forero-Schwanhaeuser S; US Medical Affairs, GSK, Durham, NC, USA., Moore A; Global Medical Affairs, General Medicines, GSK, London, UK., Noorduyn SG; Value Evidence and Outcomes, R&D Global Medical, GSK, Mississauga, ON, Canada.; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada., Paczkowski R; US Value Evidence and Outcomes, GSK, Collegeville, PA, USA. |
| Source: | Advances in therapy [Adv Ther] 2025 Feb; Vol. 42 (2), pp. 1061-1074. Date of Electronic Publication: 2024 Dec 23. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-8652 (Electronic) Linking ISSN: 0741238X NLM ISO Abbreviation: Adv Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 39714547 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Medicare Advantage Population in the United States: Outcomes of Patients with Asthma Treated with ICS/LABA Before and After Initiation with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI). – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Baptist+AP%22">Baptist AP</searchLink>; Division of Allergy and Clinical Immunology, Henry Ford Health and MI State University Health Sciences, One Ford Place, 3A32, Detroit, MI, 48202, USA. abaptis1@hfhs.org.<br /><searchLink fieldCode="AU" term="%22Germain+G%22">Germain G</searchLink>; Group d'Analyse, Ltée, Montreal, QC, Canada.<br /><searchLink fieldCode="AU" term="%22Klimek+J%22">Klimek J</searchLink>; Analysis Group, Inc, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Laliberté+F%22">Laliberté F</searchLink>; Group d'Analyse, Ltée, Montreal, QC, Canada.<br /><searchLink fieldCode="AU" term="%22Schell+RC%22">Schell RC</searchLink>; Analysis Group, Inc, Menlo Park, CA, USA.<br /><searchLink fieldCode="AU" term="%22Forero-Schwanhaeuser+S%22">Forero-Schwanhaeuser S</searchLink>; US Medical Affairs, GSK, Durham, NC, USA.<br /><searchLink fieldCode="AU" term="%22Moore+A%22">Moore A</searchLink>; Global Medical Affairs, General Medicines, GSK, London, UK.<br /><searchLink fieldCode="AU" term="%22Noorduyn+SG%22">Noorduyn SG</searchLink>; Value Evidence and Outcomes, R&D Global Medical, GSK, Mississauga, ON, Canada.; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Paczkowski+R%22">Paczkowski R</searchLink>; US Value Evidence and Outcomes, GSK, Collegeville, PA, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%228611864%22">Advances in therapy</searchLink> [Adv Ther] 2025 Feb; Vol. 42 (2), pp. 1061-1074. <i>Date of Electronic Publication: </i>2024 Dec 23. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Health+Communications+Inc%22">Health Communications Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8611864 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1865-8652 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220741238X%22">0741238X </searchLink><i>NLM ISO Abbreviation: </i>Adv Ther <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39714547 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s12325-024-03083-6 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1061 Titles: – TitleFull: Medicare Advantage Population in the United States: Outcomes of Patients with Asthma Treated with ICS/LABA Before and After Initiation with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI). Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Baptist AP – PersonEntity: Name: NameFull: Germain G – PersonEntity: Name: NameFull: Klimek J – PersonEntity: Name: NameFull: Laliberté F – PersonEntity: Name: NameFull: Schell RC – PersonEntity: Name: NameFull: Forero-Schwanhaeuser S – PersonEntity: Name: NameFull: Moore A – PersonEntity: Name: NameFull: Noorduyn SG – PersonEntity: Name: NameFull: Paczkowski R IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 02 Text: 2025 Feb Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 1865-8652 Numbering: – Type: volume Value: 42 – Type: issue Value: 2 Titles: – TitleFull: Advances in therapy Type: main |
| ResultId | 1 |
